Long versus short biliopancreatic limb in Roux-en-Y gastric bypass: short-term results of a randomized clinical trial

Background: The Roux-en-Y gastric bypass continues to be one of the most performed bariatric surgeries because of its adequate balance of outcomes, complications, and durability. Recently, the role of the biliopancreatic limb on weight loss and co-morbidity control has gained attention because it seems to have a positive impact based on limb length. Objective: To compare results at 12 months of a standard (group 1) versus a long (group 2) biliopancreatic limb bypass. Biliopancreatic limbs were 50 cm and 200 cm, and alimentary limbs were 150 cm and 50 cm, respectively. Setting: Academic Referal Center; Mexico City; Public Seeting. Methods: Randomized study with patients undergoing both types of surgeries at a single academic center from 2016 to 2018. The analysis included weight loss, co-morbidity control (diabetes and hypertension), biochemical panel, operative outcomes, and complications. Results: Two-hundred ten patients were included (105 in each group). Almost all data were homogenous at baseline. Female sex comprised 86.1% of cases, with a mean body mass index of 43.5 kg/m(2). Excess weight loss (77.6 +/- 15.7% versus 83.6 +/- 16.7%; P =.011) and total weight loss (33.5 +/- 6.4% versus 37.1 +/- 7.1%; P < .001) was higher in group 2; better HbA1C levels were also observed. Co morbidity outcomes, operative data, and complications were similar between groups. Conclusion: The Roux-en-Y gastric bypass with 200 cm of biliopancreatic limb length induces more weight loss at 12 months than a 50 cm limb length. Better HbA1C levels were also observed, but similar effects on co-morbidities and complications were noted. (C) 2021 American Society for Bariatric Surgery. Published by Elsevier Inc. All rights reserved.

Automated summary

Comparing the results at 12 months of standard versus long biliopancreatic limb bypass surgeries, it was found that surgery with a 200 cm biliopancreatic limb length induced more weight loss and improved HbA1C levels, while demonstrating similar effects on co-morbidities and complications.